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Understanding the T cell response to SARS-CoV-2 is critical to vaccine development, epide-
miological surveillance and disease control strategies. This systematic review critically eval-
uates and synthesises the relevant peer-reviewed and pre-print literature published from 01/
01/2020-26/06/2020.
Methods
For this systematic review, keyword-structured literature searches were carried out in MED-
LINE, Embase and COVID-19 Primer. Papers were independently screened by two
researchers, with arbitration of disagreements by a third researcher. Data were indepen-
dently extracted into a pre-designed Excel template and studies critically appraised using a
modified version of the MetaQAT tool, with resolution of disagreements by consensus. Find-
ings were narratively synthesised.
Results
61 articles were included. 55 (90%) studies used observational designs, 50 (82%) involved
hospitalised patients with higher acuity illness, and the majority had important limitations.
Symptomatic adult COVID-19 cases consistently show peripheral T cell lymphopenia,
which positively correlates with increased disease severity, duration of RNA positivity, and
non-survival; while asymptomatic and paediatric cases display preserved counts. People
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with severe or critical disease generally develop more robust, virus-specific T cell
responses. T cell memory and effector function has been demonstrated against multiple
viral epitopes, and, cross-reactive T cell responses have been demonstrated in unexposed
and uninfected adults, but the significance for protection and susceptibility, respectively,
remains unclear.
Conclusion
A complex pattern of T cell response to SARS-CoV-2 infection has been demonstrated, but
inferences regarding population level immunity are hampered by significant methodological
limitations and heterogeneity between studies, as well as a striking lack of research in asymp-
tomatic or pauci-symptomatic individuals. In contrast to antibody responses, population-level
surveillance of the T cell response is unlikely to be feasible in the near term. Focused evalua-
tion in specific sub-groups, including vaccine recipients, should be prioritised.
Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the novel pathogen caus-
ing coronavirus disease 2019 (COVID-19), has spread globally and was declared a pandemic
by the World Health Organization (WHO) on 11th March 2020 [1]. At the time of writing,
there have been around 57.9m confirmed cases and 1.4m deaths reported to the WHO [2].
Lack of pre-existing immunity to this novel and highly infectious betacoronavirus is likely to
be responsible for the extraordinary surge in cases worldwide.
There has been an unparalleled global effort to characterise the immune response to SARS--
CoV-2 infection, and to develop and test vaccine candidates at unprecedented speed. Under-
standing the patterns in individual- and population-level immunity will be key to informing
future decisions on implementation of non-pharmacological interventions, broader public
health policies, and strategies for vaccine delivery. While there is a rapidly growing body of lit-
erature on the antibody response to SARS-CoV-2, much less has been published on the T cell
response, despite its critical importance in antiviral immunity and vaccine development.
There are principally three areas of interest; firstly, the role of T cells in viral control and
immunopathogenesis during acute SARS-CoV-2 infection; secondly the role of T cells in
establishing durable protective immunity against reinfection; and finally, the relevance of pre-
existing cross-reactive cellular immunity from endemic human coronaviruses (HCoV), or
SARS-CoV-1 [3].
This paper focuses on summarising current understanding of the cellular response to
SARS-CoV-2 infection, specifically exploring the role that T cell-mediated immunity might
play in resistance to severe infection, clinical and virological recovery, and long-term protec-
tion–while recognising the dynamic interdependence of the two arms of the adaptive immune
response. It is the second of two linked papers summarising results from a wide-ranging sys-
tematic review of peer-reviewed and pre-print literature on the human adaptive immune
response to SARS-CoV-2 infection [4].
Methods
A systematic review was carried out according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. The protocol was pre-registered with
PROSPERO (CRD42020192528).
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Patient and public involvement
There was no patient or public involvement in the conceptualisation or design of this review.
Identification of studies
Keyword-structured searches were performed in MEDLINE, Embase, COVID-19 Primer and
the Public Health England library [5] for articles published between 01/01/2020-26/06/2020. A
sample search strategy can be found in S1 Appendix in S1 File. We also consulted subject area
experts to identify relevant papers not captured through the database searches.
Definitions, inclusion, and exclusion criteria
We included studies in all human and animal populations, and carried out in all settings (labo-
ratory, community and clinical—encompassing primary, secondary and tertiary care centres),
relevant to our research questions. We excluded case reports, commentaries, correspondence
pieces or letter responses, consensus statements or guidelines, and study protocols. We
included studies reporting on any aspect of the T cell response irrespective of follow-up dura-
tion, and on correlates of that response. We defined “correlates” to include (among others)
age; gender; ethnicity; the presence of intercurrent or co-morbid disease e.g. diabetes, cardio-
vascular, chronic respiratory disease; and primary illness severity, proxied by the WHO’s dis-
tinction between “mild”, “moderate”, “severe” and “critical” COVID-19 [6], or by requirement
for intensive care.
Selection of studies
Studies were independently screened on title, abstract and full text by two team members
(working across four pairs), and disagreements arbitrated by one of the review leads.
Data extraction, assessment of study quality, and data synthesis
Data were extracted in duplicate from each included study into a bespoke Microsoft Excel tem-
plate (S2 Fig in S1 File). Where both pre-print and peer-reviewed versions of a report were
returned through searches, results were extracted from both if substantial differences in
reported data were identified; if little difference was found, only the peer-reviewed version was
retained.
Critical appraisal for each included study was performed in duplicate using a version of the
MetaQAT 1.0 tool that was adapted for improved applicability to the basic science and labora-
tory-based studies that are common in this field [7]. The adapted MetaQAT tool was used to
gather both qualitative feedback on study quality and scaled responses (yes/no/unclear) to
questions around study reliability, internal and external validity, and applicability, with narra-
tive assessment of quality used to inform review findings. Full details of this process can be
found in S3 Appendix and S4 Fig in S1 File.
Due to the degree of methodological heterogeneity across included studies, formal meta-
analysis was not performed. Results are synthesised narratively in the sections that follow.
Ethical approval
This was a systematic review based on analysis of openly published secondary data and did not
involve humans. No ethical approval was required.
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Results
Descriptive overview of included studies
A total of 9,223 records were identified through searches conducted for the review after de-
duplication, and a further five through expert consultation, of which 61 papers were included
(see PRISMA flowchart in Fig 1).
Key characteristics of included studies are further summarised in Table 1. Of the included
reports, 34 (56%) were peer-reviewed journal papers [3, 8–40]. Two animal-based, basic sci-
ence studies were included [30, 41] but the overwhelming majority of reports were in humans,
for which the most common designs were case-control (n = 26, 43%) [10–12, 14, 17, 21, 23,
25–29, 31, 32, 37, 38, 40, 42–50] and cohort (n = 22, 36%) [8, 13, 15, 16, 20, 22, 34, 36, 39, 51–
62]. 50 studies (82%) considered participants sampled from hospital settings [8, 9, 11–29, 31–
40, 42, 43, 45, 46, 48–50, 53, 54, 56–65]. Most studies originated from China (n = 32, 52%)
[11–13, 15–21, 23–29, 31–39, 43, 45, 50, 53, 61, 63]. Only five studies (8%) specifically exam-
ined cellular responses in children [15, 19, 33, 35, 39]; while only one study examined differ-
ences by gender [24], and none by ethnicity (see Table 2).
Fig 1. PRISMA flowchart documenting the search and screening process for this review.
https://doi.org/10.1371/journal.pone.0245532.g001
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What follows is a narrative synthesis of the main study findings grouped according to topic
area. In each section we highlight main limitations of the included papers, with more detailed
summaries of each study, the methods and assays applied, as well as specific limitations further
elaborated on in the S1 File. Overall, many important study limitations were identified in all
topic areas (individual study critical appraisal details are given in S5 Appendix in S1 File), the
details and implications of which are explored in the discussion.
Acute phase T cell response and association with cytokine release syndrome
General features of the T cell response in the acute phase. The majority of included
papers commented on general aspects of the T cell response to SARS-CoV-2 infection in the
acute phase of illness, though the duration of this period was not explicitly defined. Methodo-
logical reporting was of variable quality across included studies: in n = 10 papers (16% of the
included set) methods were not clearly described, and for the remainder, approaches to quan-
tification of the T cell response varied. For example, Laing et al. partnered a total lymphocyte
count from a full blood count and flow cytometry to derive estimates of absolute T cell subset
counts based on the gated percentages [54], while other studies used direct quantification of
Table 1. Summary of descriptive statistics for included studies.





Case control 26 43%
Cohort 22 36%
Case series 7 11%
Basic science study 3 5%
Narrative review 1 2%
Systematic review with meta-analysis 1 2%





Country from which study population was drawn
China 32 52%
Europe excl. UK (France, Germany, Italy, Spain, Sweden, Netherlands) 13 21%
USA 3 5%
UK 3 5%
Other countries 6 11%
Multiple populations 2 3%
N/A (lab or animal based) 2 3%
Sampling context
Hospital 50 82%
Mixed hospital and community 1 2%
Community 6 10%
Laboratory (animal) 2 3%
N/A (review) 2 3%
https://doi.org/10.1371/journal.pone.0245532.t001
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lymphocyte subsets, such as TruCount™ [58]. A majority of the studies used either recognised
or in-house flow cytometry tools.
Higher quality studies consistently found evidence for reduction of total peripheral T cell
counts in symptomatic adult patients during the acute phase, often accompanied by increased
activation of remaining T cells and evidence of functional ‘exhaustion’, as defined by expres-
sion of the markers PD-1 and Tim-3; however, findings regarding specific subsets were more
mixed. Three well-designed cohort studies [22, 32, 54] showed reductions in both CD4+ and
CD8+ T cell counts in clinical cohorts ranging in size from 30 to 187 patients, while two found
evidence of greater reductions in CD8+ (cytotoxic) than CD4+ (helper) T cells [22, 54]. A
cohort study (n = 17 patients) only found evidence of reduction in CD4+ but not CD8+ T
cell counts on comparing patients with ‘aggravated’ (or clinically progressive) with non-aggra-
vated disease [34]. A cohort study of 64 patients from Italy showed that T cell frequencies were
maintained in patients with mild and asymptomatic disease [51]. Broadly similar findings
emerge from a range of high-quality case-control studies, typically with much larger sample sizes.
Three hospital-based case-control studies with sample sizes ranging from 102 to 522 patients
found evidence of globally reduced lymphocyte counts (CD3+, CD4+ and CD8+ T cells) in the
acute phase [12, 26, 37]. These findings were also reflected in two summary reviews [3, 67].
The first, a medium-quality meta-analysis incorporating data on 5,912 patients across 35 pub-
lished/pre-print reports, showed that total numbers of B cells, T cells and natural killer (NK) cells
were all significantly decreased in COVID-19 patients’ peripheral blood [67]. This picture of
peripheral T cell lymphopenia in COVID-19 patients is reinforced by findings from a larger body
of observational studies though many of these had significant methodological limitations [e.g.
16–18]. Notably, four studies considering T cell responses in paediatric COVID-19 cases univer-
sally demonstrated comparable T cell counts to healthy paediatric controls, or higher counts
when compared against adult cases [19, 33, 35]. The one study to evaluate responses in asymp-
tomatic adult cases (n = 20) found little change in the circulating T cell counts within this group
also [51].
Five studies provided more detailed analysis of T cell phenotypes in severe and/or critical
disease, with overall suggestions of higher T cell activation with increasing disease severity,
alongside depletion of specific subsets that reverses with clinical recovery [13, 27, 51, 60, 62]. A
well-conducted study by Anft et al. (n = 53) found significant peripheral depletion in critical
patients of activated (e.g. HLA-DR+) memory/effector T cells that co-express tissue migratory
markers (e.g. CD11a), when compared to severe and moderate cohorts [62]. Lower frequencies
of terminally differentiated T-cell subsets (TEMRA) were found in patients with both severe
and critical disease. Importantly, recovery from acute respiratory distress syndrome (ARDS)
was accompanied by a restoration of CD11a+ T cell subsets. Two studies of critically ill patients
identified stronger inflammatory cytokine T cell responses to Spike (S) protein [62], and to S,
membrane (M) and nucleocapsid proteins (NP), with greater reactivity by CD4+ compared to
CD8+ cells [60] within this group, respectively. Carsetti et al. reported an overall increase in
activated (e.g. HLA-DR+) CD4+ T cells in 16 patients across both mild and severe disease but
found that HLA-DR+ CD8+ cells were specifically increased in severe disease [51]. Two studies
also found increased numbers of activated T cells in patients with severe and critical disease,
with reversal upon disease remission [13, 27].
Accompanying T cell dysregulation, a cytokine release syndrome (CRS)-like clinical picture
occurs in many patients with severe SARS-CoV-2 infection [68]. Elevated levels of many pro-
inflammatory cytokines, such as interleukin-6 (IL-6), and to lesser degree, interleukin-10 (IL-
10), and tumour necrosis factor alpha (TNF-α) were identified in patients in four studies [3,
69–71]. Concentrations of pro-inflammatory cytokines such as IL-6 positively correlated to
severity of disease and with lymphopenia [8, 11, 16, 17, 21, 22, 27, 36, 37, 61, 65, 67]. A large
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peer-reviewed study with 1,018 participants reported over ten-fold increases in IL-6 levels
amongst COVID-19 cases, and found that serum IL-6>20pg/mL was strongly associated with
in-hospital mortality (OR 9.78, p<0.001) on multivariable regression analysis [21]. A pre-print
Table 2. Evidence on clinical and demographic correlates of T cell response to SARS-CoV-2 infection from studies included in this review (� disease severity was
defined in various ways in included studies; for some according to intensive care unit admission; a number used the Chinese National Health Commission defini-
tion [66]).







1. • One study evaluated T cell responses in asymptomatic patients (n = 20) and found little change in the circulating T cell frequencies within this group
[51].
Moderate disease • Reduced numbers of both CD4+ and CD8+ T cells in moderate and severe cases, alongside increased numbers of activated CD4+ and CD8+ T cells
expressing PD-1 or Tim-3; as well as potential reductions in cytotoxic potential and polyfunctionality were reported in one narrative review [3].
Severe or critical disease Cell counts
• A medium quality meta-analysis found that patients with severe disease had statistically significant, two-fold decreases in both CD4+ and CD8+ T cells, as
well as in CD3+ T cells (1.7-fold) and overall lymphocyte number (1.44-fold), alongside statistically significant increases in neutrophils (1.33-fold) and
overall leukocytes (1.2-fold) [67].
• A large study (N = 599) reported reduced total, CD4+, and CD8+ T cells being associated with more severe disease, comparing n = 43 ICU-admitted
patients with non-ICU-admitted patients, and comparing critical/severe non-ICU patients with mild/moderate non-ICU patients (as per Chinese
national definitions�) [37].
• Other large studies [11, 18, 32, 36] showed comparable findings, and 3 studies also reported reduced CD3+ cells in more severe disease [18, 32, 36];
however, one only found significant cell count differences for critical vs severe disease, and not for severe vs moderate disease [18].
Cell ratios
• Six studies reported marked increases in CD4/CD8 ratio (due to increases in CD4+ but reductions in CD8+ cells) in severe and critical patients compared
to those with moderate disease [22, 25, 36, 62, 65]. The last of these also showed CD8
+
T cell counts were much slower to normalise than CD4+ in patients
with severe disease [25].
• Two studies however, reported significant reductions in CD4+, but not in CD8+, T cells in severe disease (n = 452), or ‘aggravated’ disease, defined as
clinically progressive at 7 days (n = 17) [26, 34].
• A small study from Iran reported increased CD8 expression in ICU patients relative to healthy controls, quantified by flow cytometry as mean
fluorescence intensity (MFI), with no significant differences seen in CD4/CD8 ratio, or CD4+ T cell MFI [40].
Clinical
endpoint
Survival vs non-survival • Two studies with large cohorts followed up COVID-19 patients until death or discharge, both conducting multivariate analysis. Luo et al. (n = 1018),
reported significantly lower CD3+, CD4+ and especially CD8+ counts in non-survivors than survivors, and found that CD8+ T cell counts <165 cells/μL (OR
5.93) were independently associated with mortality after adjustment for age, sex and comorbidities [21]. Liu et al. (n = 340) reported that lower helper T
cells (OR 0.22) and higher CD4/CD8 ratio (OR 4.8) were highly significant predictors of mortality [63].
• Whilst also reporting lower CD8+ counts in non-survivors throughout the disease course, Wang et al. (n = 157) also found that non-survivors had lower
CD4+ counts only evident in middle and late stages of disease, and that non-survivors had a lower CD4/CD8 ratio [29].
• Based on 28 deaths amongst 187 patients, Xu et al. demonstrated that total T cell counts <500/μl, CD3+ counts <200/μl, CD4+ or CD8+ counts <100/μ as
well as B cell counts <50/μL, were significantly associated with risk of in-hospital death, however this is only on univariate analysis [32].
• In a cohort of n = 548, Chen et al. reported significantly elevated neutrophil-to-lymphocyte ratio (NLR), platelets-to-lymphocytes ratio (PLR), reduced
peripheral CD3+, CD4+ and particularly CD8+ counts in non-survivors [36]. He et al. (n = 204) reported that T cell levels continued to fall until death in
non-survivors, whilst in survivors with severe disease, levels increased after 15 days and normalised after 25 days of treatment [11].
RNA persistence • Four small but high or medium quality clinical cohort studies from China showed that slower resolution of PCR-positivity is associated with reductions in
peripheral T cells.
• Jiang et al. (n = 23) found that the baseline abnormalities in CD3+, CD4+ and CD8+ T cells underwent robust recovery in patients who became RNA
negative 2 weeks after diagnosis, whilst they did not do so in those who remained persistently positive [12].
• Liu et al. compared 37 cases who remained positive at day 20, with 37 patients at their point of diagnosis, as well as 54 healthy controls, and showed that
both the persistently positive and control groups had higher CD3+ and CD4+ levels, suggesting that these subsets do normalise despite viral persistence [45].
• In a similar study, though with a persistence threshold of 15 days, Dong et al. (n = 18) also found global reductions across CD3+, CD4+ and CD8+ subsets
for persistent positives, which increased between admission and discharge; as well as significant negative correlation between overall T cell count and
duration of positive nucleic acid test [38].
• Liu et al. (n = 39) also reported higher global T and B cells in patients becoming RT-PCR negative within 14 days [20].
Co-morbid disease status • Three studies considered the effect of comorbid status, all originating from China and spanning patients with non-severe, severe and critical clinical
presentations [11, 20, 39]. Two had significant methodological limitations [20, 39].
• One study (n = 204) found significantly lower total lymphocyte and lymphocyte subset counts in patients with comorbidities compared with those without
(though “comorbidities” not defined) [11].
• The second (n = 39) found statistically significant differences in CD8+ counts between patients with comorbid disease and those without (p = 0.046), but
no difference in CD4+ counts—although here again the range of comorbidities considered was not defined [20].
• The final study compared outcomes in a paediatric cohort with or without “allergic disease” (not clearly defined) and showed no effect on clinical course,
total lymphocyte or lymphocyte subset counts [39].
Demographic Age Older adults • A high-quality clinical cohort study and a medium-quality case-control study, both from China, reported lower T cell total and subset counts, including
CD3+, CD4+, CD8+ subsets, for older patients aged 60 or over [11, 37].
Children • Four medium-quality studies—1 case control and 3 case series—considered cellular responses in children in samples from China, all showing comparable
CD3+, CD4+ and CD8+ counts to healthy paediatric controls, or where the comparison group was adults, higher T cell counts across subsets [19, 33, 35].
However, potential confounders such as disease severity or comorbidities were not controlled for in these studies.
Sex • One medium-quality case series (n = 27) from China examined differences in cytokine secretion by sex of cases, showing reductions in CD4+ and CD8+
count for all patients irrespective of gender but more generalised cytokine responses were observed among male participants than females, for IL-6, TNF-α
and procalcitonin–although the statistical significance of these differences was not tested [24].
https://doi.org/10.1371/journal.pone.0245532.t002
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systematic review reported 1.93-fold increases in IL-6 and 1.55-fold increases in IL-10 for severe
patients [67]. In line with this, another large study (n = 548) reported significantly increased IL-
6 levels in non-survivors compared with survivors [36]. Correspondingly, levels of IL-6 and IL-
10 appeared to be negatively correlated with total T cell and subset counts across all included
studies, and showed normalisation in tandem with clinical resolution [37]. Findings for other
interleukins, IL-1, IL-2, IL-4 and IL-8, were more mixed [11, 16, 17, 27, 37, 61, 67].
Dynamics of the T cell response over the acute phase. Seven studies reported longitudi-
nal data on the T cell response, mostly focusing on within-hospital trends, with a maximum
follow-up range of 14–44 days following symptom onset [8, 9, 11, 12, 32, 45, 59]. Overall, the
available evidence suggests that peripheral T cell depletion is closely linked with both disease
severity and viral load in the acute phase, and recovery of counts can occur rapidly following
clinical or virological recovery, especially in more mild disease. Two large and well-conducted
case-control studies (n = 103 and n = 187) found that low T cell counts on admission increased
steadily over the course of admission. Subsequent recovery of lymphocyte count was roughly
consistent with clinical improvement [12, 32]. One study found evidence of significant
decreases in counts of CD3+ T, CD4+ T, CD8+ T, and NK cells in COVID-19 patients com-
pared with healthy controls (all p<0.05) on admission. In a subset of n = 23 patients followed
up two weeks after initial presentation, those newly negative for SARS-CoV-2 RNA on poly-
merase chain reaction (PCR) showed the most dramatic recoveries in T cell subset counts [12].
Two studies reported longitudinal trends in detail at regular follow-up intervals; the first, a
cohort study from Italy involving 18 patients (nine mild and nine severe cases), found that low
total lymphocyte counts in severe cases were stably maintained for up to 20 days post-admis-
sion, with little discernible difference between T cell subsets [8]. The second, a French cohort
study (n = 15) of predominantly elderly patients admitted to intensive care, found that CD8+
counts fell to their lowest value by days 11–14 after symptom onset (p = 0.03), with recovery
thereafter, but noted a slightly later nadir for CD4+ (days 19–23) and with no significant
change in the overall CD4/CD8 ratio throughout the 35-day follow-up period [59].
Correlates of the T cell response
The number of studies addressing demographic and clinical correlates of the T cell response
was small and many potentially important variables such as ethnicity were not addressed. Key
findings from this literature are summarised in Table 2. The largest single body of work exam-
ined relationships between T cell response and disease severity, based predominantly on stud-
ies in the hospital setting.
In regard to clinical correlates, peripheral counts appeared undisturbed in asymptomatic
disease, significantly depleted in moderate or severe disease, and with disturbances to the
CD4/CD8 ratio in severe or critical disease. The single study including asymptomatic cases
was of good quality, although limitations included relatively small sample size and poor report-
ing of sample selection methods [51]. Evidence regarding moderate and severe disease was
consistent across several good quality studies with larger sample sizes [32, 37, 62] and was also
reflected in two reviews [3, 67].
Lower peripheral T cell counts were associated with non-survival, as reflected in two larger
studies which conducted multivariable analyses and found independent associations for spe-
cific subsets [21, 63]; with persistent RNA-positivity, primarily in smaller studies with some
risk of selection bias; and with older age, including in one large higher quality study [37].
Many studies were limited by poor reporting of sample and control selection methods, and
by some variability in their definitions of clinical severity (most as per WHO, however some
were based on Chinese national guidance).
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Viral cross-reactivity of T cells
Eight studies explored cross-reactivity of T cells between SARS-CoV-2 and related human
coronaviruses within small, adult-only samples of cases and controls [10, 42, 44, 46, 47, 49, 52,
55]. Using activation-induced marker (AIM) assays, Grifoni et al. detected SARS-CoV-2-reac-
tive CD4+ T cells against a range of S and non-S epitopes in 12/20 ‘pre-pandemic’ US donors
[10] while Weiskopf et al. reported low levels of cross-reactivity in only 2/10 ‘pre-pandemic’
German donors [49]. Using an interferon gamma (IFN-γ) enzyme-linked immunosorbent
spot (ELISpot) assay, Gallais et al. found some T cell cross-reactivity mainly to the S2-domain
of the S protein in 5/10 ‘pre-pandemic’ French donors [52] and Le Bert et al. found T cells spe-
cific to NP and non-structural proteins 7 and 13 (NSP7, NSP13) in SARS-CoV-1/2 unexposed
donors [55]. The latter Singapore-based study also reported robust SARS-CoV-2 NP-reactivity
in T cells from SARS-CoV-1 convalescents, with these memory cells persisting for 17 years
after the SARS outbreak [55].
Amongst controls recruited during the pandemic, but confirmed as antibody- and PCR-
negative, S-reactive T cells were demonstrated in 23/68 controls in a high-quality German
study [42]; and in 12/14 controls in a smaller Russian study, including one household contact
of a COVID-19 case. The latter study also included a smaller group of ‘pre-pandemic’ donors
(n = 10), who had significantly lower frequency and magnitude of reactivity than the controls
recruited during the pandemic, hinting at a possible protective effect of cross-reactive T cells
[47]. In contrast, Peng et al. found no SARS-CoV-2-specific T cell responses in either ‘pre-pan-
demic’ or ‘during-pandemic’ antibody-negative UK controls (n = 19) [46].
Notably, studies consistently found a lower frequency and magnitude of T cell response as
well as a differential pattern of immunodominance in reactive unexposed controls relative to
SARS-CoV-2 convalescents, with low homology between COVID-19 convalescent T cell epi-
topes and known epitopes from endemic human coronaviruses (HCoV). An Australian study
found that frequencies of T follicular helper (TFH) cells specific to HCoV-HKU1 were higher
amongst COVID-19 convalescents (n = 41) than uninfected controls (n = 27), suggesting
boosting of HKU1-specific responses following SARS-CoV-2 exposure, and hinting at a coro-
navirus-specific TFH response (study findings are further elaborated on below in the context
of T-cell population characterisation) [44].
The evidence suggests that a degree of cross-reactivity of T cell responses between human
coronaviruses may be relatively common; however, the significance of these findings for indi-
vidual and population susceptibility to SARS-CoV-2 remains unclear. Additionally, the evi-
dence is limited by very small sample sizes, uncertain validity of ‘during-pandemic’ controls,
and heterogeneity in assay methods.
Characterisation of T cell subpopulations and protective immunity
Twelve studies characterised T-cell subpopulations, including magnitude, functionality and
phenotypic characteristics, post-acute COVID-19 infection. Timing of sampling post disease
onset and duration of follow-up differed both within and between studies, many of which
were conducted on small study populations, with sampling methods rarely reported (S5
Appendix in S1 File). One French contact-tracing study demonstrated SARS-CoV-2-specific T
cell responses against structural (S, M, and NP) and accessory proteins in all nine index cases,
in samples collected at 47–69 days post symptom-onset, as well as in 6/8 PCR-negative or
untested contacts (of whom five were symptomatic), in samples collected up to 80 days post-
onset [52]. A UK-based study of COVID-19 convalescents (28 mild cases, 14 severe cases)
characterised the T cell response using IFN-γ ELISpot assays on samples taken at least 28 days
post symptom onset [46]. A strong and broad SARS-CoV-2-specific T cell response was
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generally elicited but varied between individuals. T cell response breadth (p = 0.010) and mag-
nitude (p = 0.002) were significantly higher in patients who recovered from severe disease in
comparison to mild cases. Sub-set evaluation demonstrated CD8+ T cells mediated a greater
proportion of responses detected to S and M or NP epitopes. No difference in the levels of
polyfunctional T cells was observed between mild and severe disease. Differences were
observed in the cytokine profiles of CD8+ T cells targeting different viral antigens, with the M/
NP-specific CD8+ T cells displaying wider functionality compared to those targeting S-protein
(p = 0.0231). In those with mild disease, M/NP-specific CD8+ T cells were significantly higher
than S-specific T cells. This trend was not observed in those with severe disease [46].
These findings complement the study by Grifoni et al. (discussed above) which found that
NP, M and S proteins contain the immunodominant epitopes for both CD4+ and CD8+ T cells
[10]. No significant differences in the cytotoxic potential was detected between mild and severe
disease. Specific SARS-CoV-2-reactive T cells were not frequently observed in healthy, unex-
posed individuals. Furthermore, the magnitude of T cell responses in COVID-19 patients cor-
related with related antibody titres, including anti-S and anti-NP. Another study stimulated
peripheral blood mononuclear cells (PBMCs) from 18 COVID-19 patients ranging in disease
severity with two overlapping peptide pools spanning the full S region [42]. Twelve patients
had detectable CD4+ T cell reactivity against the first peptide pool, which contained N-termi-
nal epitopes including the receptor binding domain (RBD). Fifteen patients displayed reactive
CD4+ T cells against the second peptide pool, which contained C-terminal epitopes processing
higher homology with HCoVs. Among the non-reactive cases most had critical disease [42].
Le Bert et al. assayed peripheral blood T cell responses to NP and NSP7 and NSP13 of the
large SARS-CoV-2 proteome using an IFN-γ ELISPOT assay. Samples were obtained from 24
individuals who had experienced mild to severe COVID-19. For all patients, IFN-γ spots were
observed following stimulation with NP peptide and nearly all displayed responses against
multiple regions of NP. A further sub-analysis demonstrated T cell recognition of multiple
regions of SARS-CoV-2 NP among recovered patients (8/9) [55].
Six studies reported on the phenotypic and target profile of T cell subsets. One study per-
formed an in-depth characterisation of humoral and cellular immunity against the S protein in
samples taken from 41 adults who had recovered from mild-moderate SARS-CoV-2 infection
(five requiring hospitalisation but not mechanical ventilation) and 27 controls. Expanded pop-
ulations of S-specific memory B cells and circulating cTFH cells (which play a critical role in
supporting antigen-specific B cells to initiate and maintain humoral immune responses) were
detected [44]. The frequencies of unstimulated cTFH cells were comparable between SARS--
CoV-2 convalescent and uninfected groups. In general, robust cTFH cells activity to the
SARS-CoV-2 S-protein was observed among the convalescent group, whereas responses to
RBD-specific cTFH were significantly lower (p<0.0001). The antigen reactivity of S-specific
non-cTFH CD4 memory (CD3+CD4+CD45RA-CXCR5-) cells revealed similar trends with
strong recognition of SARS-CoV-2 and smaller frequencies of RBD-specific T cells. High
plasma neutralisation activity was also found to be associated with increased S-specific anti-
body, but notably also with the relative distribution of S-specific cTFH subsets [44].
Another study analysed the T cell response in samples taken from 31 COVID-19 patients
[13]. Disease severity was classified in accordance with US National Institute of Health classifi-
cation system [72], with a total of n = 2, n = 19, and n = 10 participants being categorized as
having asymptomatic, mild, and moderate/sever disease, respectively. None of whom required
intensive care or oxygen supplementation. A central memory phenotype (CD45RO+, CCR7+),
followed by an effector memory phenotype (CD45RO+, CCR7-) were predominate within the
S-reactive CD4+ T cell population. An effector memory, followed by the terminal effector cells
(CD45RO-, CCR7-) were the predominant phenotypes among antigen-specific CD8+ T cells.
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A significant increase in activated (CD38+, HLA-DR+) CD4+ T cells was detected among cases.
Further T cell response characterisation showed CD4+ and CD8+ T cell activation in response
to full-length S-protein exposure, and the M-protein response was significantly stronger
(p = 0.0352). A correlation between the magnitude of T-cell and humoral responses was
reported (anti-RBD IgG and CD8+ T-cell response). However, this relationship was weakly sta-
tistically significant (r = 0.386 p = 0.0321), whereas an interdependence was reported between
the magnitude of CD8+ and CD4+ responses (r and p values not presented) [47]. Three addi-
tional studies reported on the presence of the effector memory phenotype, two of which stud-
ied hospitalised patient populations, and the third study analysed samples from returning
travellers. Minervina and colleagues reported detection of T cell clones within both the effector
and central memory subpopulations, in samples obtained from two returnees from countries
with high SARS-CoV-2 transmission [64]. Similarly, Weiskopf et al., in their study of 10
COVID-19 patients who developed ARDS, reported that peripheral SARS-CoV-2-specific
CD4+ T-cells typically had a central memory phenotype (based on CD45RA and CCR7 expres-
sion), whereas the majority of virus-specific CD8+ T-cells had a CCR7- effector memory
(TEM) or TEMRA phenotype [49]. In contrast, a study of four COVID-19 positive paediatric
cases with mild disease, and five uninfected controls, found no difference in the effector or
central memory phenotypes of the CD8+ and CD4+ populations compared with controls [33].
A small study conducted a phenotypic analysis of circulating SARS-CoV-2-specific T cells
in samples obtained 20–47 days post positive PCR from individuals recently recovered from
mild SARS-CoV-2 infection. The analysis was conducted using combination SARS-CoV-
2-specific T cell detection with CyTOF. IFN-γ producing S-specific CD4+ and CD8+ T cells
were detected, suggestive of a S-specific T helper (Th)1 response, where as Th2 and Th17 line-
ages were not detected among S-specific CD4+ T cells [73].
Evidence of potential protective T cell-mediated immunity is provided by one US-based
study that measured the cellular response in rhesus monkeys (n = 9 cases, n = 3 controls)
upon repeat challenge with pooled S peptides, day 35 post initial infection [30]. Based on
IFN-γ ELISpot assays, cellular immune responses were observed in the majority of animals,
with a trend toward lower responses in the lower dose groups. Intracellular cytokine stain-
ing assays demonstrated induction of both S-specific CD4+ and CD8+ T cell responses. Post
re-challenge, very limited viral RNA was observed in bronchoalveolar lavage (BAL) on day
one following re-challenge in three animals, with no viral RNA detected at subsequent time-
points. In contrast, high levels of viral RNA were observed in the concurrently challenged
naive animals. However, these findings to do not exclude the possibility that protection was
antibody-dependent rather than due to T cell immunity exclusively, and longer-term analy-
ses are needed [30].
Discussion
This review narratively synthesises findings from 61 studies examining human T cell responses
to SARS-CoV-2 published before the end of June 2020. Given the exceptional speed and vol-
ume of developments in COVID-19 research, further evidence has accumulated in the inter-
vening months. In this section we summarise key findings from the review and contextualise
them against new data published since our searches were completed in late June 2020; impor-
tantly, we have not identified any reports that challenge the central findings of this review.
Summary of key findings
Acutely, adult COVID-19 patients exhibit a depletion of T cells in the peripheral blood, the
extent of which is positively correlated with disease severity, whereas asymptomatic patients
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and children tend to have preserved peripheral T cell counts. This suggests an important rela-
tionship between pathogenesis and the circulating T cell pool. Observed lymphopaenia in
adult COVID-19 patients is likely to be multifactorial in origin, with redistributive effects, apo-
ptotic loss [74], and possibly reduced mobilisation of lymphocytes from bone marrow, all play-
ing a part. Prior work has also shown an association between IL-6 production and blockade of
lymphopoiesis; although the extent to which this mechanism operates in COVID-19 has yet to
be investigated [75]. Regarding age differences, it has been speculated that children may
receive protection from a diverse naive T cell repertoire, with adults of increasing age at higher
risk due to immunosenescence [76]. At the time of searching, few studies had explored the
relationship between T cells, age and clinical severity, with appropriate statistical adjustment,
however, a recent study examining all three branches of the adaptive immune response (CD8
+ T cells, CD4+ T cells, and neutralising antibodies), found that older age and scarcity of naïve
T cells were associated with un-coordinated adaptive responses and more severe disease [77].
Another recent study reported more robust S-specific T cell responses in adults (mean age
61.05 years) compared with children (mean age 13.34 years) [78].
There is emerging evidence of cytokine over-production, in particular IL-6 and IL-10, as
part of immunopathogenesis within COVID-19; however, drivers of these observed changes
are still not fully understood. A recent pre-print report from a Brazilian research group
describes infection of CD4+ T cells by SARS-CoV-2, with subsequent high expression of IL-10
by infected cells [79]. If these data are robust to peer-review and can be replicated elsewhere,
this finding may represent one of the contributory factors. Trials of immunomodulatory
agents including those that inhibit the IL-6 pathway in COVID-19 patients are also underway
[80], although initial results for one of these agents, tocilizumab, proved disappointing [81].
Although less comprehensive, longer-term data suggest that T cell reductions are transient,
with rapid recovery of counts within days to weeks of clinical recovery and PCR negativity.
This supports the hypothesis that T cells are sequestered rather than destroyed, although the
observation of similarly depleted T cell numbers in the broncho-alveolar lavage samples of
severe patients indicates that T cells are not simply recruited en masse to infected tissues [82].
In the context of well-recognised variations in COVID-19 clinical outcomes by age, ethnicity
and co-morbid status, there is a striking shortage of robust evidence on demographic correlates
of the T cell response to SARS-CoV-2. We identified a single study considering gender-related
effects on T cells, and eight studies considering cellular responses with age (a majority of these in
paediatric patients with or without adult controls). We identified no studies evaluating other
potentially important determinants, including ethnicity. These constitute important gaps in the
evidence, which persist even in more recent literature, and should be addressed in future studies.
Evidence characterising cellular immune responses suggest enduring T cell immunity, with
phenotypic profiles consistent with helper and memory T cell functions and evidence of activ-
ity against multiple viral targets. Variation in viral targets is observed between disease severity
and based on one study, the breadth and magnitude of the T cell response were significantly
higher in patients who recovered from severe compared to mild disease. Responses were also
detected in individuals who experienced mild infection. However, this evidence derives from
small, observational studies conducted on samples taken from participants at varying time
points, and with selection criteria rarely described. The longevity of this T cell immunity and
the degree of protection it provides remains unclear, though recent pre-print papers from
studies with longer follow-up report durability of virus-specific T cells for as long as 6–8
months following infection [83, 84]. Recent epidemiological and animal model evidence hints
at the protective function of T cells [85, 86], and is supported by identification of detectable
virus-specific T cell responses in seronegative COVID-19 convalescents [87–89], and in unin-
fected individuals with known exposure [90].
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With regards to T cell cross-reactivity, included studies reported variable prevalence of
SARS-CoV-2-reactive T cells in unexposed controls. These studies were limited by small sizes
and assay heterogeneity, but there was consensus around the lower frequency and magnitude
of T cell responses, and differential epitope dominance, in reactive controls relative to SARS--
CoV-2 convalescents. More recent studies conducting detailed characterisation of the T cell
epitopes governing cross-reactivity have found similarity with common cold coronaviruses
[89, 91], with one study reporting pre-existing T cell responses in 81% of unexposed controls
and data suggestive of lower pre-existing cross-reactivity in hospitalised COVID-19 cases com-
pared with mild cases [89]. Several models of the potential impact of pre-existing cross-reactiv-
ity on individual and population immunity have been proposed [92], and methodologies
allowing distinction between pre-existing T cell responses, and those arising from SARS-CoV-
2 infection, are a growing focus of investigation [93].
Strengths and limitations
This study is the first systematic review on the T cell immune response to SARS-CoV-2, utilising
robust methods for searching, screening, and critically appraising both pre-print and peer-
reviewed literature. While a number of narrative reviews are available [94, 95], some of which
focus on specific aspects of cellular immunity [67, 96], our review is broader in both scope and
comprehensiveness, and is intended as a foundation for ongoing systematic evidence synthesis.
Limitations arise from the methodology applied, and from the nature of the underlying evi-
dence. First, while the search strategy was broad in choice of keywords and inclusion of pre-
print publications, it is possible that some results were missed, particularly on pre-print servers
for which structured searches are more challenging.
Additional limitations arise from the nature of the underlying evidence base on which this
review draws. Variations in reporting practice present major challenges for critical appraisal
and weighting of evidence. For example, narrative reviews–popular in this field–have limited
methods reporting. Further difficulty is introduced through variations in treatment protocols,
clinical severity and case definitions used in included studies, and varying methods adopted
for T cell counts, functionality, phenotypes, and assay validation. Not only do these factors
introduce substantial methodological heterogeneity, thereby limiting quantitative syntheses of
data; they are also critical to the study of T cell immunity to SARS-CoV-2 as the assays are
evolving and yet to be formally validated and standardised.
Importantly, many of the studies also had significant methodological limitations, most
notably, small sample sizes accompanied by minimal reporting on selection methods for par-
ticipants and controls, which introduces substantial risk of selection bias. This risk is further
compounded where only subsets of samples are characterised in greater depth, or small sub-
cohorts are followed-up longitudinally, with little explanation of how these sub-groups are
selected. Consequently, it is challenging to draw inferences and to generalise findings to the
population-level, limiting applications to wider practice and policy. Other issues affecting the
validity and reliability of data, such as lack of valid controls and lack of statistical analyses to
control for confounders, for example when testing associations with demographic or clinical
correlates, are also commonly encountered issues within the evidence base.
Finally, as a consequence of the urgency of conducting research and disseminating findings
during this pandemic, academic conventions have often been circumvented. Many findings
were initially (and sometimes solely) reported through pre-print papers, which have not
undergone the scrutiny of peer-review. Caution should be applied when drawing inferences
from these data, and we have taken care in this study to distinguish clearly between preprint
and peer-reviewed publications in reporting findings. Furthermore, we noted large variations
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in the ethical approval processes that authors of individual studies appeared to have followed,
and the extent to which informed consent was sought from participants. The implications for
the integrity of future research are potentially grave and will need to be comprehensively
addressed in the interests of ethically sound research practice in future.
Policy implications and onward research questions
Many unanswered questions remain, such as the durability of and protection afforded by
virus-specific T cell responses, and their relative importance in protection from reinfection
compared with antibodies. More data is also needed on the demographic correlates of T cell
responses and the significance of cross-reactive cellular immunity.
An important application of findings from T cell response studies will be towards evalua-
tion of the rapidly growing number of SARS-CoV-2 vaccine candidates, a number of which
are now in or emerging from clinical trials [97]. In parallel with clinical data from COVID-19
patients, vaccine developers are frequently reporting on T cell immunogenicity from early
phase evaluations. While this is notably lacking for some prominent candidates (including
inactivated vaccines from Sinovac [98], Beijing Institute of Biological Products/Sinopharm
[99], and the Chinese Academy of Medical Sciences [100]), other frontrunners (including
mRNA vaccines by Moderna [101] and Pfizer/BioNTech [102], and non-replicating viral-vec-
tored vaccines by Oxford University [103], Gamaleya Research Institute [104], and CanSino
[105]), have successfully demonstrated vaccine-induced T cell responses against S-protein epi-
topes. While these data are encouraging, given the wide range of potential T cell epitopes, it is
worth exploring whether multi-peptide platforms such as traditional inactivated whole-virus,
or novel virus-like particles, may provide more robust immunity through harnessing the full
potential of the T cell response, as compared with S-focused mRNA and viral-vectored plat-
forms. This is supported by data from recent studies demonstrating that non-S proteins make
up the most immunodominant T cell epitopes following infection [106], and that more diverse
T cell responses are associated with milder disease [89]. It will also be important to conduct
Phase 3 and post-implementation evaluation of vaccine effectiveness in groups with high prev-
alence of prior infection, such as health and care staff, who will be a priority group for vaccine
deployment following licensure. In addition to antibody testing, baseline assessments of virus-
specific T cell reactivity are likely to be highly useful for this purpose.
Current estimates of population immunity rely solely on seroprevalence studies, however
in the context of evidence for cellular responses in seronegative exposed individuals, and the
potential waning of antibody responses over time, current surveillance methods are likely to
be underestimating both exposure and immunity. A more developed understanding of the
role of T cells in long-term protection will be helpful to policy makers in terms of modelling
where population-level immunity lies and informing long-term surveillance and immunisa-
tion strategies. However, by contrast with antibody testing–a mainstay of immune surveillance
for many communicable diseases–existing T cell assays are difficult to standardise and hard to
scale, therefore unlikely to be deliverable at population level within the timeframe of the
SARS-CoV-2 pandemic. In the short-term, emphasis may need to be placed on determining
the utility of T cell assays to guide clinical and public health actions at the individual level, par-
ticularly in patients with immunosuppression, or those at the extremes of age. In parallel, ade-
quately-powered and controlled studies providing deep immunophenotyping of T cells, B
cells, and comprehensive characterisation of immune responses in mild or asymptomatic
cases, and in vaccine recipients, will yield insights about the interdependence and relative
importance of cellular and humoral responses. Over the long-term, development of scalable T
cell assays may help to strengthen population immune surveillance systems.
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Conclusions
A complex picture is emerging concerning the T cell response to SARS-CoV-2 infection,
including the interplay between compartments of the immune system, and the balance
between protective versus pathological responses. Inferences are limited by methodological
limitations within studies, and heterogeneity between studies. Evaluation of T cell responses at
scale is currently infeasible and the benefits of such an approach as yet unclear. Findings from
targeted testing may carry important clinical and policy implications for public health inter-
ventions within at-risk sub-groups, for understanding mechanisms of vaccine efficacy, and for
informing long-term population immunisation and surveillance strategies.
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